BioCentury
ARTICLE | Financial News

Column Group leads Escient's $40M series A

May 11, 2018 5:18 PM UTC

Escient Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by The Column Group. Also participating were 5AM Ventures and Osage University Partners.

Escient is developing compounds targeting GPCRs, including from the family of Mas-related G protein-coupled receptors, initially for neuro-immuno-inflammatory and autoreactive diseases. The company hopes to bring two compounds into the clinic by 2021...